Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their price objective on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th.

Minerva Neurosciences Price Performance

Shares of Minerva Neurosciences stock opened at $2.86 on Wednesday. Minerva Neurosciences has a one year low of $2.26 and a one year high of $13.49. The stock’s 50-day moving average is $3.18 and its 200 day moving average is $3.74. The firm has a market cap of $20.00 million, a price-to-earnings ratio of -0.64 and a beta of 0.15.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, sell-side analysts expect that Minerva Neurosciences will post -1.89 EPS for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.